This trial is testing whether molecularly targeted oral medications called talazoparib and
tazemetostat can be safely combined for the treatment of prostate cancer, and whether the
combination is effective in shrinking or preventing the growth of metastatic prostate cancer.
The names of the study drugs involved in this study are:
- Talazoparib
- Tazemetostat